Sinopharm Tech Holdings Limited filed its resubmitted Monthly Return for the period ended 31 January 2026, confirming that both authorised and issued share capital remained unchanged during the month.

Authorised Capital • Ordinary shares: 12.80 billion units, par HKD 0.0125, representing HKD 160.00 million. • Convertible preference shares: 3.20 billion units, par HKD 0.0125, representing HKD 40.00 million. Total authorised capital therefore held steady at HKD 200.00 million. The structure reflects the November 2024 capital reorganisation, which subdivided each HKD 0.3125 share into 25 shares of HKD 0.0125.

Issued Shares • Ordinary shares in issue (ex-treasury): 633.69 million, unchanged from December 2025. • Convertible preference shares in issue: 1.48 billion, also unchanged. • No treasury shares were held or transferred during the month.

Share Options • Outstanding options under the 2021 Share Option Scheme totalled 5.28 million, with no exercise or cancellation in January. Up to 12.10 million shares remain available for future grants under the scheme.

Convertibles • HKD 148.02 million in non-voting convertible preference shares, equivalent to 1.48 billion underlying ordinary shares, were outstanding. No conversions occurred in January; the instruments are convertible at HKD 0.10 per share within a ten-year window ending November 2034.

Public Float Compliance Sinopharm Tech confirmed compliance with Hong Kong listing rules on public float. As at 31 January 2026, public shareholders held 24.99% of issued ordinary shares, marginally below the customary 25% threshold but deemed sufficient under applicable rules.

Capital Raising Activity The company reported zero new share issuance, zero treasury share movements and no proceeds raised during the month.

Governance Confirmation Management certified that all securities-related activities during January 2026 were duly authorised and in full compliance with Hong Kong listing regulations and relevant laws.